Hironori Yoshida
Kyoto, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Correction: Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.
Journal: Cancer research
Published: June 26, 2026
Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 18, 2025
Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation.
Journal: Nature communications
Published: September 17, 2025
Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.
Journal: Cancer research
Published: August 04, 2025
Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer.
Journal: Nature communications
Published: July 10, 2025
The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study.
Journal: Journal of cancer research and clinical oncology
Published: November 20, 2024
Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancer.
Journal: Molecular and clinical oncology
Published: November 20, 2024
Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.
Journal: Cancer science
Published: November 14, 2024
ICOS+CD4+ T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis.
Journal: JCI insight
Published: September 16, 2024
Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study.
Journal: BMC cancer
Published: July 05, 2024
Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study.
Journal: Journal of pharmaceutical health care and sciences
Published: May 17, 2024
Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report.
Journal: Molecular and clinical oncology
Published: December 16, 2023
Last Updated: 09/26/2026